Search results
9 lut 2024 · Each class of medicines blocks the virus in different ways. Treatment involves mixing medicines from different classes to: Account for medicine resistance, called viral genotype. Keep from creating new medicine-resistant strains of HIV. Suppress the virus in the blood as much as possible.
30 mar 2020 · Pregnant women fulfilling any of the criteria mentioned in the section on “Recommended Treatment Start” should start treatment with the recommended and suitable drugs for first-line HIV-2 ART from Week 12–15 onwards, selecting the safest and best-known substances in terms of potential maternal and fetal toxicity.
2 lut 2022 · Women living with HIV have demanded to be seen beyond their childbearing capacity, and to have access to all available treatment options. They continue to advocate for increased choice regarding prevention and treatment options, and to be heard.
26 lip 2024 · Long-acting injectable lenacapavir proves effective in HIV prevention for women. 26 July 2024. Departmental update. Reading time: 2 min (587 words) WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women.
22 lip 2024 · Treatment. There is no cure for HIV infection. It is treated with antiretroviral drugs, which stop the virus from replicating in the body. Current antiretroviral therapy (ART) does not cure HIV infection but allows a person’s immune system to get stronger. This helps them to fight other infections.
Despite tremendous advances in HIV research over the last 40 years, women—particularly women of color, young women, and transgender women—remain disproportionately affected by HIV. 1,2 Further research is critical to understanding optimal ways to prevent, treat, and cure HIV and associated comorbidities across women’s lifespans.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
